The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Expires: July 31, 2015
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
ABIVAX SA SPONSORED ADS 00370M103 8,699,219 78,125 SH SOLE 78,125 0 0
AGOMAB THERAPEUTICS NV SPONSORED ADS 00860C102 16,140,984 1,538,702 SH SOLE 1,538,702 0 0
EVOMMUNE INC COM SHS 30054Y107 43,620,352 1,897,362 SH SOLE 1,897,362 0 0
INVENTIVA SA ADS 46124U107 10,090,905 1,818,181 SH SOLE 1,818,181 0 0
KESTRA MED TECHNOLOGIES LTD SHS G52441105 53,715,177 2,695,192 SH SOLE 2,695,192 0 0
MINERALYS THERAPEUTICS INC COM 603170101 43,125,032 1,591,917 SH SOLE 1,591,917 0 0
NYXOAH S A SHS B6S7WD106 1,524,406 522,057 SH SOLE 522,057 0 0